Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL

Criteria: Inclusion Criteria: * age:14-65 years;Eastern Cooperative Oncology Group (ECOG)score≤3;expected survival≥3 months * patients with ALK-positive Anaplastic Large Cell Lymphoma diagnosed by immuno-histochemistry (IHC) or fluorescence in situ hybridization (FISH); * Refractory or relapse after at least 4 cycles of CHOP（cyclophosphamide, hydroxydaunomycin, Oncovin, and prednisone）regimen * acceptable hematological indicators, no chemotherapy contraindications; * total bilirubin ≤ 1.5 times the upper limit of normal (ULN), alanine aminotransferase (ALT) ≤ 2.5 x upper age limit (ULN), if the abnormal laboratory parameters are considered to be caused by lymphoma, patients Eligible conditions should be adjusted to be incorporated into the group; * At least one measurable lesion by CT or PET-CT（Positron Emission Tomography-Computed Tomography）; * exclude other major diseases, normal heart and lung function; * Female patients of childbearing age are negative for pregnancy test; * Cooperate with follow-up; * There are no other related treatments including traditional Chinese medicine, immunotherapy, and biologic therapy (except for the treatment of anti-bone metastases and other symptoms); * Signing informed consent \*: Pathological histology must be consulted by a pathologist at a provincial hospital. Exclusion Criteria: * rejecting providing blood preparation; * allergic to drug in this study and with metabolic block; * rejecting adopting reliable contraceptive method in pregnancy or lactation period; * uncontrolled internal medicine disease(including uncontrolled diabetes,severe incompetence cardiac,lung,liver and pancreas）； * with severe infection; * with primary or secondary central nervous system tumor invasion; * with immunotherapy or radiotherapy contraindication; * ever suffered with malignant tumor; * having peripheral nervous system disorder or dysphrenia; * with no legal capacity,medical or ethical reasons affecting research proceeding; * participating other clinical trials simultaneously; * adopting other anti-tumor medicine excluding this research; * Patients with immunodeficiency, such as primary immunodeficiency syndrome or organ transplant recipients * Human immunodeficiency virus (HIV)-positive patients * the researchers considering it inappropriate to participate in the study.